OWD
LUMO

Osborn Williams & Donohoe’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Osborn Williams & Donohoe’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-67
Closed -$1K – 686
2019
Q1 		$1K Buy
+67
New +$999 ﹤0.01% 746

Other funds holding LUMO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Osborn Williams & Donohoe's LUMO Position: Q2 2019 in Review

Osborn Williams & Donohoe sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2019, closing a stake of 67 shares — an estimated $1K sold.

Osborn Williams & Donohoe first reported a position in LUMO in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 68 funds tracked by Wall St. Rank hold LUMO as of Q2 2019.

  • Osborn Williams & Donohoe reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Osborn Williams & Donohoe sold 67 Lumos Pharma, Inc. Common Stock shares in Q2 2019, an estimated $1K.
  • Osborn Williams & Donohoe first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Osborn Williams & Donohoe's Lumos Pharma, Inc. Common Stock position peaked at $1K in Q1 2019.
  • 68 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2019.

Based on Osborn Williams & Donohoe's 13F filing for Q2 2019, filed 26 Jul 2019.